MMP9 and osteosarcoma: Conversely, the overexpression of PDGFD, in either non-metastatic osteosarcoma or metastatic osteosarcoma, resulted in a decrease in MMP9, β-catenin, and ZEB expression, while E-cadherin expression was increased (Fig. 8h, j).